New Generation Vaccines

Myron M. Levine, Gordon Dougan, Michael F. Good, Gary J. Nabel, James P. Nataro, Rino Rappuoli, Myrone M. Levine, Margaret A. Liu

• Publisher: CRC Press
• Year: 2016
• eBook ISBN: 9781040168738
• Topic: Medicine
• Subtopic: Infectious Diseases

Highlighting the latest activities and initiatives of prominent organizations working in the vaccine industry such as the Bill and Melinda Gates Foundation, The Global Alliance for Vaccines and Immunization, WHO, UNICEF, the World Bank, New Generation Vaccines, Fourth Edition, details steps developing countries have taken toward research, development, manufacture, and regulation of several new vaccines for widespread use.

This text will:

cover the current state-of-the-art techniques in vaccine development – including the successes and the failures
trace vaccine development from the bench to public health with regard to both FDA and European Union regulations
investigate improved methods for immunizing large populations, and the use of needless vaccinations
discuss the advancements in the heavily government-funded areas for developing vaccines against potential bioterror and infectious disease agents as well as the immunization of large population bases for diseases like: Anthrax, Smallpox, Ebola, West Nile, SARS, and others
Updated throughout with new cutting-edge information on recent breakthroughs and developments.

NEW TO GENERATION VACCINES, FOURTH EDITION:

highlights the latest activities of prominent organizations in the vaccine industry
covers the current techniques in vaccine development
investigates improved methods for immunizing large populations

Table of contents

• Cover Page
• Halftitle Page
• Title Page
• Copyright Page
• Foreword
• Preface
• Contents
• Contributors
• 1 Vaccines and Vaccination in Historical Perspective
• 2 Developing Vaccines in the Era of Reverse Vaccinology
• 3 Initial Clinical Evaluation of New Vaccine Candidates
• 4 Speciali Issues in Performing Vaccine Trials in Developing! Countries
• 5 Long-Term Evaluation of Vaccine Performance: Methodological Issues for Phase III and Phase IV Studies
• 6 Ethical Considerations in the Conduct of Vaccine Trials in Developing Countries
• 7 Vaccine Economics: Assuring] That Vaccines Are Developed for and Available in Developing Countries
• 8 Development and Supply of Vaccines: An Industry Perspective
• 9 Reaching Every Child: Achieving Equity in Global Immunization
• 10 A Paradigm for International Cooperation: The GAVI Alliance
• 11 Economic Analyses of Vaccines and Vaccination Programs
• 12 An Overview of U.S. Food and Drug Administration Licensure of Vaccines
• 13 Assuring Vaccine Quality by Strengthening Regulatory Agencies: The Work of the World Health Organization
• 14 Vaccine Safetya
• 15 Manufacturing of Vaccines
• 16 Polio Eradication: Ongoing Innovation to End an Ancient Scourge
• 17 Recent Advances in Immunology That Impact Vaccine Development
• 18 Modulating Vaccine Responses with Innate Immunity
• 19 Immunodominance, Deceptive Imprinting, and Immune Refocusing Technology
• 20 Standardization and High-Throughput Measurement of T-Cell Responses to Vaccines
• 21 Transition to High-Throughput Laboratory Assays to Evaluate Multivalent Vaccines
• 22 The Challenge of Vaccine Protection in Very Young Infants
• 23 The Challenge of Inducine] Vaccine Protection in the Elderly
• 24 Vaccination and Autoimmunity
• 25 Adjuvants for the Future
• 26 TLR9 Agonists for Immune Enhancement of Vaccines
• 27 Use of Genetically or Chemically Detoxified Mutants of Cholera and Escherichia coli Heat-Labile Enterotoxins as Mucosal Adjuvants
• 28 Recent Developments» in Nonliving Antigen Delivery Systems
• 29 Virus-Like Particles as Vaccines and Vaccine Delivery Systems
• 30 Subunit Vaccines Produced Usine] Plant Biotechnology
• 31 Lipopeptide-Based Vaccines
• 32 Vaccines Based on Dendritic Cell Biology
• 33 Vaccinici Virus and Other Poxviruses as Live; Vectors
• 34 Replication-Defective and Competent Adenovirus Recombinants as Vaccine Vectors
• 35 RNA Virus Replicon Vaccines
• 36 Engineering of Attenuated Salmonella enterica Serovars for Use as Live Vector Vaccines
• 37 DNA Vaccines
• 38 Overview of Heterologous Prime-Boost Immunization Strategies
• 39 Mucosal Immunization and Needle-Free Injection Devices
• 40 Advances in Transcutaneous Vaccine Delivery
• 41 Rationalizing Childhood Immunization Programs: The Variation in Schedules and Use of Combination Vaccines
• 42 Meningococcal Conjugate and Protein-Based Vaccines
• 43 Post-Licensure Impact of Haemophilus influenzae Type b and Serogroup C Neisseria meningitidis Conjugate Vaccines in Industrialized Countries
• 44 Haemophilus influenzae Type b Disease Burden and the Impact of Programmatic Infant Immunization in Developing Countries
• 45 Pneumococcal Protein-Polysaccharide Conjugate Vaccines
• 46 Pneumococcal Common Proteins and Other Vaccine Strategies
• 47 Polysaccharide-Based Conjugate Vaccines for Enteric Bacterial Infections: Typhoid Fever, Nontyphoidal Salmonellosis, and Escherichia coli O157:H7
• 48 Attenuated Strains of Salmonella enterica Serovars Typhi and Paratyphi as Live Oral Vaccines Against Enteric Fever
• 49 Oral Cholera Vaccines
• 50 Novel Vaccines Against Tuberculosis
• 51 Influenza
• 52 Chimeric Vaccines Against Japanese Encephalitis, Dengue, and West Nile
• 53 Vaccines Against RotavirusGastroenteritis
• 54 Novel Strategies for Immunizing Infants in Developing Countries Who Are Too Young to Receive the Currently Licensed Measles Vaccines
• 55 Challenges and Prospects for the Development of an HIV Vaccine
• 56 Vaccine Strategies to Prevent Dengue
• 57 Vaccination Against the Hepatitis C Virus
• 58 Vaccines Against Respiratory Syncytial Virus and Parainfluenza Viruses
• 59 Cytomegalovirus Vaccines
• 60 Epstein-Barr Virus Vaccines
• 61 Herpes Simplex Vaccines
• 62 Development of Vaccines to Prevent Group A Streptococcal Infections and Rheumatic Fever
• 63 Vaccines Against Group EB Streptococcus
• 64 Overview of Live and Subcellular Vaccine Strategies Against Shigella
• 65 Vaccines Against Enterotoxigenic Escherichia coli
• 66 Multivalent Shigella Enterotoxigenic Escherichia coli Vaccine
• 67 Vaccines for Staphylococcus aureus Infections
• 68 Chlamydia trachomatis Vaccines
• 69 Malaria Vaccines» in Clinical Development: Introduction and Recombinant/Subunit Approaches
• 70 Gene-Based Malaria Vaccines
• 71 Pre-erythrocytic and Asexual Erythrocytic Stage Whole-Organism Malaria Vaccines
• 72 Vaccines Against Leishmania
• 73 Vaccines Against Schistosomiasis
• 74 Vaccines Against Entamoeba histolytica
• 75 Hookworm Vaccines
• 76 Improved Smallpox Vaccines
• 77 Anthrax Vaccines
• 78 Tularemia Vaccines
• 79 Vaccines Against Plague
• 80 Development of Vaccines for Ebola and Marburg Viruses: Efficacy and Regulatory Considerations
• 81 Therapeutics and Vaccines Against Hendra and Nipah Viruses
• 82 Vaccines Against Lassa Fever
• 83 Hantavirus Vaccines
• 84 SARS Vaccines
• 85 Cancer-Specific Vaccines
• 86 Vaccines Against Human Papillomaviruses
• 87 Vaccines Against Alzheimer’s and Other Neurodegenerative Diseases
• 88 Vaccination for Autoimmune and Other Chronic Inflammatory Disorders
• 89 Immunotherapies To Treat Drug Addiction
• Index